Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bcl-2-related antisense therapy.

Yolanda Gutiérrez-Puente1, Pablo Zapata-Benavides, Ana M Tari

  • 1Departamento de Microbiología e Inmunología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, Monterrey, N.L., México.

Seminars in Oncology
|July 26, 2002
PubMed
Summary

Bcl-2 proto-oncogene inhibition shows promise in leukemia and lymphoma, but its role in breast cancer is complex. Bcl-2 antisense oligonucleotides may not be a universally effective therapeutic strategy for all cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of Concern for JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.

The Journal of clinical investigation·2025
Same author

Epigenetic modulation of BARD1 to enhance anti-VEGF therapy.

Cell reports. Medicine·2025
Same author

Encapsulation of Curcumin and Gemcitabine: Cytotoxic Effect and Mechanisms of Death in Lung Cancer.

Advances in pharmacological and pharmaceutical sciences·2025
Same author

Controlled release of curcumin and gemcitabine from mucoadhesive chitosan-gelatin polymeric ovules: Cytotoxic effects on cervical cancer cells.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2025
Same author

Cytokine-driven modulation of WT1 and IL-10 in lung cancer progression.

Translational lung cancer research·2025
Same author

Risk Factors Associated with the Seroprevalence of Leptospirosis in Small Ruminants from a Semi-Arid Region of Mexico.

Pathogens (Basel, Switzerland)·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The bcl-2 proto-oncogene is highly expressed in various hematologic malignancies and solid tumors.
  • Bcl-2 protein inhibits apoptosis, contributing to tumor cell survival during cancer therapies.
  • Antisense oligonucleotides targeting bcl-2 mRNA are being investigated to suppress Bcl-2 expression.

Purpose of the Study:

  • To evaluate the therapeutic potential of Bcl-2 antisense oligonucleotides in solid tumors, specifically breast cancer.
  • To investigate the paradoxical role of Bcl-2 in breast cancer, considering its association with both resistance and favorable prognosis.
  • To discuss the implications of Bcl-2 targeting for breast cancer treatment strategies.

Main Methods:

  • Review of existing laboratory and clinical data on Bcl-2 expression and antisense oligonucleotide therapy.

Related Experiment Videos

  • Analysis of Bcl-2's role in chemoresistance and endocrine resistance in breast cancer cell lines.
  • Examination of the prognostic significance of Bcl-2 levels in breast cancer patients.

    • Main Results:

    • Bcl-2 inhibition sensitizes lymphoma and leukemia cells to radiation and chemotherapy.
    • Bcl-2 overexpression appears to induce endocrine and chemoresistance in breast cancer cells.
    • High Bcl-2 levels in breast cancer are paradoxically associated with favorable prognostic factors.

    Conclusions:

    • The efficacy of Bcl-2 antisense oligonucleotides in solid tumors like breast cancer requires further investigation due to Bcl-2's complex role.
    • Bcl-2 may not be an ideal therapeutic target in breast cancer, contrasting its utility in hematologic malignancies.
    • Understanding the dual role of Bcl-2 is crucial for developing effective targeted therapies for breast cancer.